

Colleagues,

Each new development in the COVID-19 pandemic has presented unique challenges, and the proliferation of the Omicron variant is no exception. The lack of effectiveness of most monoclonal antibody preparations required major changes from health care systems in order to deliver these agents effectively. Beaumont is now happy to announce we are able to provide the one currently available mAb with activity against the Omicron variant, Sotrovimab, at three locations. Beaumont, Troy and Beaumont Outpatient Campus, Lenox began last week, and Beaumont, Dearborn began service on Jan. 25.

The Emergency Use Authorization indications for Sotrovimab are identical to those you've been accustomed to for casirivimab-imdevimab or bamlanivimab-etesevimab: a patient with proven COVID-19 infection, within 10 days of their symptoms starting, and at least one risk factor for severe disease (see attached fact sheet for providers). Given the very limited current supply of Sotrovimab, the state of Michigan has directed systems to further restrict usage, and at this point only recommends it for patients who are immunocompromised or for those patients who are pregnant or elderly and not up to date with vaccinations (see MDHHS communication). We are following these guidelines, though we hope these indications will be able to be expanded in the near future.

Sotrovimab is administered as a single dose over 30 minutes and patients need to be monitored for one hour after administration. In a clinical trial of over 1000 adults with at least one risk factor for severe disease it decreased the rate of COVID-related hospitalization from more than 5.3% to 1%. Side effects are similar to those you're familiar with from other monoclonal antibodies. There are no dosage adjustments for renal or hepatic dysfunction, no drug interactions and no contraindications. It can be ordered in Epic/*one*Chart (see attached screenshots) or via the attached paper form and directed to the infusion center of your choosing.

Thanks, as always, for your continued understanding and dedication to work through these challenging times. If you have questions about Sotrovimab, feel free to reach out to me.

Paul Chittick, M.D.
Section Head, Infectious Diseases &
International Medicine
Beaumont Hospital, Royal Oak
Paul.chittick@beaumont.edu